Browsing Tag
PROTAC
5 posts
Why ESR1 mutation targeting is critical in metastatic breast cancer treatment
FDA approves VEPPANU. Discover why ESR1 mutation targeting is reshaping metastatic breast cancer treatment and what it means next.
Arvinas wins first FDA-approved PROTAC as ARVN stock tests investor patience
PROTAC drugs finally have FDA validation. Arvinas now faces the harder question: can VEPPANU become a commercial oncology asset?
General Proximity inks Daiichi Sankyo deal to push precision small molecules into oncology
General Proximity partners with Daiichi Sankyo to develop proximity-based cancer drugs using OmniTAC. Discover how this biotech is redefining drug discovery.
Can vepdegestrant outperform elacestrant in the race for ESR1-mutant breast cancer dominance?
Vepdegestrant shows stronger PFS benefit than elacestrant in ESR1-mutant breast cancer. Can it become the new standard? Explore data, safety, and market outlook.
PROTAC vs SERD: Is protein degradation the future of endocrine resistance treatment?
Vepdegestrant challenges oral SERDs with PROTAC innovation. Explore trial results, safety, and the future of protein degradation in breast cancer care.